Rituximab (RTX) is an anti-CD20 antibody used in ANCA-associated vasculitis (AAV) for induction and maintenance of remission.
Retrospective study of 38 patients (35 with GPA and with 3 with CSS) treated with RTX between April 2004 and September 2011 for active disease. 58% of the patients had renal involvement. The cumulative cyclophosphamide (CYC) dose was 14g (0-250). Twelve patients (32%) were treated with combination CYC-RTX at initiation.
RTX was initiated as two 1g infusion 2 weeks apart (RA protocol) and thereafter 2g RTX was administered annually to achieve long-term B cell depletion. Patients were closely monitored during 46.5 (2-88) months follow-up with clinical and serological surveillance. They received a median of 5 (1-10) rounds of RTX for a cumulative dose of 8g (2-13) Had lower levels of total Ig after the first 3 RTX rounds and had also lower levels during RTX maintenance. 
